|
Devicemakers See Mixed Results in Second Quarter Earnings
Boston Scientific saw sales for its implantable cardioverter defibrillators (ICD) bounce back after a monthlong shipment hold and vows from physicians to switch to other devices.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives